The U.S FDA granted this test the BREAKTHROUGH DEVICE designation
because of it’s ability to fulfill an unmet medical need and potentially save lives
FDA BREAKTHROUGH DEVICE
Covered by Most
Private Insurance Plans
The test is covered for qualified patients by most private insurance plans. Depending on the specifics of the patient’s policy, an out-of-pocket fee may be required.
Only Requires a
Standard Blood Draw
The test only requires a standard 10ml blood draw that can be stored and transported at room temperature
High Sensitivity
for Early Stage Detection
The test is specifically designed to catch early stage pancreatic cancer. including cancers in Stage 1 and 2
The BT-Reveal Early Pancreatic Cancer Test offers a new way for people with an elevated risk to check for the earliest signs of pancreatic cancer. The test can only be prescribed by a doctor and is intended for use as a molecular test that complements other techniques for detecting pancreatic cancer including MRI, EUS, and CT scans.
The BT-Reveal Early Pancreatic Cancer Test utilizes patented DNA methylation technology that can detect faint tumor DNA signatures in the blood, even at extremely low concentrations. This means the test can catch early stages of pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) when symptoms may not yet be present and while the cancer is still able to be successfully treated through surgery or other techniques)
The BT-Reveal Early Pancreatic Cancer Test is available exclusively through BREAKTHROUGH GENOMICS. The company providers advanced genetic tests and blood-based tests for the the early detection of cancer. BREAKTHROUGH GENOMICS’ laboratory in Irvine, California is certified in the U.S. through CLIA (Clinical Laboratory Improvements Act) and by CAP (College of American Pathologists) to perform high complexity clinical test. The test is currently being offered as Laboratory Developed Test (LDT) and as such surpasses the lab’s requirements to provide the test to at risk individuals.
Please note: a positive result does not guarantee an individual has cancer. For all positive results, additional testing is recommended including through MRI, endoscopic ultrasound (EUS), CT Scans, and ERCPs. A negative result does not rule out the presence of cancer.